In a nutshell......







"Due to major inefficiencies in the Dendreon organization involving the paperwork used to get a patient on board with Provenge, our practice has decided to treat one patient and wait to see if we are reimbursed, but more importantly to step back and "take a pulse". Based on the inefficiencies I will mention below, we are attempting to identify shortfalls and inaccuracies that would threaten our ability to continue prescribing this treatment. Essentially, we have to develop our own in-office system for the paperwork flow, and assign roles of each certain employee in the paperwork process".
 






In a nutshell.....product overpriced and not selling. Reps leaving, DSM backstabbing and throwing reps under bus, Executive overpaid bad rejects from other failures. Product has no chance.